Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization of Novavax COVID-19 Vaccine, adjuvanted in patients 12 years and older with COVID-19, according to an announcement from the FDA.1
Novavax joins the growing list of COVID-19 vaccines including vaccines from Pfizer-BioNTech, Moderna, and Johnson & Johnson’s Janssen.2
The Novavax COVID-19 vaccine, adjuvanted is comprised of the SARS-CoV-2 spike protein and Matrix-M adjuvant.
According to the FDA, adjuvants are integrated into vaccines to increase the immune response. In this particular vaccine, the spike protein is produced in insect cells. Moreover, the Matrix M-adjuvant includes saponin extracts from the bark of the native Chilean soapbark tree.
As with other available COVID-19 vaccines, there are some reported side effects. The most commonly reported side effects reported by Novavax vaccine recipients included redness and swelling at the injection site, pain/tenderness, fatigue, muscle pain, joint pain, headache, nausea/vomiting, and fever.
The vaccine is administered as a 2-dose primary series, with those 2 doses given 3 weeks apart.
For more information on the Novavax COVID-19 vaccine, adjuvanted, visit www.FDA.gov.
References:
1. Novavax covid-19 vaccine, adjuvanted. FDA. August 19, 2022. Accessed August 22, 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted
2. COVID-19 Vaccination. Centers for Disease Control and Prevention. August 19, 2022. Accessed August 22, 2022. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
First patient dosed in RECONNECT trial of RE104 for postpartum depression
July 23rd 2024Reunion Neuroscience Inc. initiates phase 2 trial of RE104, a novel short-duration psychedelic treatment for postpartum depression, aiming to provide rapid and effective relief for affected mothers.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Supreme Court retains nationwide access to mifepristone
Published: June 13th 2024 | Updated: June 13th 2024In a unanimous ruling, the Supreme Court rejected a challenge by antiabortion doctors, maintaining nationwide access to mifepristone for medication abortions and reversing a lower court's decision to restrict the pill's availability.
Read More